within Pharmacolibrary.Drugs.ATC.A;

model A04AA55
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.97,
    Cl             = 0.00011333333333333333,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.072,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016833333333333332,
    Tlag           = 18.0,            
    Vdp             = 0.15,
    k12             = 22.7,
    k21             = 22.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A04AA55</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Palonosetron is a selective 5-HT3 receptor antagonist used to prevent nausea and vomiting caused by chemotherapy and surgery. The combination ATC code A04AA55 may include palonosetron in combination with other antiemetics (such as netupitant) to enhance antiemetic effectiveness. Palonosetron is approved and commonly used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for healthy adult volunteers (both sexes) receiving palonosetron in combination with netupitant, typically as a fixed-dose oral combination (Netupitant-Palonosetron; Akynzeo).</p><h4>References</h4><ol><li><p>Lorusso, V, et al., &amp; Aapro, M (2015). Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting. <i>Future oncology (London, England)</i> 11(4) 565–577. DOI:<a href=\"https://doi.org/10.2217/fon.14.260\">10.2217/fon.14.260</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25360998/\">https://pubmed.ncbi.nlm.nih.gov/25360998</a></p></li><li><p>Calcagnile, S, et al., &amp; Timmer, W (2013). Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. <i>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</i> 21(10) 2879–2887. DOI:<a href=\"https://doi.org/10.1007/s00520-013-1857-9\">10.1007/s00520-013-1857-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23748441/\">https://pubmed.ncbi.nlm.nih.gov/23748441</a></p></li><li><p>Calcagnile, S, et al., &amp; Timmer, W (2015). Evaluation of the effect of food and age on the pharmacokinetics of oral netupitant and palonosetron in healthy subjects: A randomized, open-label, crossover phase 1 study. <i>Clinical pharmacology in drug development</i> 4(5) 377–386. DOI:<a href=\"https://doi.org/10.1002/cpdd.192\">10.1002/cpdd.192</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27137147/\">https://pubmed.ncbi.nlm.nih.gov/27137147</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A04AA55;
